Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Satellos Bioscience Inc. (NASDAQ:MSLE) has earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $18.00.

A number of analysts have issued reports on the stock. Leerink Partners assumed coverage on shares of Satellos Bioscience in a report on Monday, April 6th. They issued an “outperform” rating and a $20.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Satellos Bioscience in a report on Monday, May 18th. Canaccord Genuity Group upgraded shares of Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th.

Satellos Bioscience Stock Performance

Shares of NASDAQ MSLE opened at $7.11 on Friday. The company has a market cap of $148.00 million, a P/E ratio of -4.44 and a beta of 1.54. The company has a fifty day moving average of $6.85. Satellos Bioscience has a 52-week low of $4.56 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). As a group, equities analysts anticipate that Satellos Bioscience will post -1.69 earnings per share for the current fiscal year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.